OBJECTIVE: Based on the rapid health technology assessment（ HTA）

to evaluate the efficacy

safety and economical efficiency of Shenfu injection in the treatment of cardiac failure

so as to provide evidence-based evidence for clinical rational drug application. METHODS: HTA reports

systematic reviews/Meta-analyses and pharmacoeconomic studies on Shenfu injection in the treatment of cardiac failure were involved by overall retrieving CNKI

Wanfang database

CBM

EMBase

PubMed and the Cochrane Library

qualitative description was adopted to conduct analysis and summary on the involved studies

and quality evaluation on the literature and its methodology were performed. RESULTS: Totally 14 studies were involved

13 of which were systematic reviews/Meta-analyses

1 was pharmacoeconomic study

no HTA report was retrieved. The analysis result indicated that the combination of Shenfu injection and western conventional therapy in the treatment of cardiac failure had obvious advantages in promoting clinical effective rate

improving TCM syndrome score

reducing brain natriuretic peptide level

improving left ventricular ejection fraction

increasing cardiac output

improving heart pump function

reduce N-terminal B-type pronatriuretic peptide level

promoting 6-min walking distance

improving left ventricular shortening fraction and reducing readmission rate of patients with cardiac failure; however

the research conclusions on reducing the left ventricular end diastolic diameter and mortality were inconsistent; meanwhile

no obvious adverse drug reactions occurred during medication

and the safety was good. CONCLUSIONS: Shenfu injection has good effectiveness and safety in the treatment of cardiac failure. In the future

it can be considered to further carry out standardized clinical efficacy observation and pharmacoeconomic research on this drug

and then supplement its economic evaluation evidence for the treatment of heart failure.